
Keymed Biosciences, Inc. (2162) Receives a Buy from Sinolink Securities

I'm PortAI, I can summarize articles.
Sinolink Securities analyst maintained a Buy rating on Keymed Biosciences, Inc. yesterday and set a price target of HK$83.29.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Keymed Biosciences, Inc. has an analyst consensus of Strong Buy, with a price target consensus of HK$88.61.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

